Inhibikase Therapeutics I... (IKT)
NASDAQ: IKT
· Real-Time Price · USD
1.84
0.13 (7.60%)
At close: Aug 15, 2025, 3:00 PM
Inhibikase Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | 79.57K | 116.41K | 64.52K | 123.44K | n/a | 6.55K | 46.03K | 1.94K | 328.46K | 1.36M | 1.41M |
Cost of Revenue | n/a | n/a | n/a | 6.57K | 6.57K | 6.57K | 6.57K | 159.2K | 5.04K | 5.04K | n/a | 2.98M | 3.02M | 3.39M | 3.15M | 2.38M | 2.43M |
Gross Profit | n/a | n/a | n/a | -6.57K | -6.57K | -6.57K | 73K | -42.79K | 59.48K | 118.4K | n/a | -2.98M | -2.97M | -3.39M | -2.83M | -1.02M | -1.02M |
Operating Income | -14.6M | -12.93M | -5.83M | -5.05M | -4.78M | -4.4M | -4.77M | -6.2M | -4.71M | -4.33M | -4.51M | -4.64M | -4.64M | -5.04M | -4.47M | -2.63M | -2.63M |
Interest Income | 919.27K | 796.12K | 49.41K | 90.93K | 132.72K | 225.63K | 173.68K | 424.44K | 237.17K | 55.92K | 18.54K | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -13.68M | -12.13M | -5.78M | -4.96M | -4.65M | -4.18M | -4.6M | -5.78M | -4.48M | -4.28M | -4.49M | -4.64M | -4.64M | -5.04M | -4.47M | -2.64M | -2.64M |
Net Income | -13.68M | -12.13M | -5.78M | -4.96M | -4.65M | -4.18M | -4.6M | -5.78M | -4M | -4.17M | -4.49M | -4.64M | -4.64M | -5.04M | -4.47M | -2.64M | -2.64M |
Selling & General & Admin | 5.25M | 5.74M | 1.64M | 1.97M | 2.02M | 1.39M | 1.62M | 1.78M | 1.93M | 1.34M | 1.54M | 1.66M | 1.67M | 1.65M | 1.64M | 1.61M | 1.6M |
Research & Development | 10.51M | 7.19M | 4.19M | 3.08M | 2.75M | 3M | 3.23M | 4.54M | 2.85M | 3.05M | 2.98M | 2.98M | 3.02M | 3.39M | 3.15M | 2.38M | 2.43M |
Other Expenses | -1.16M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -64.52K | -63.57K | n/a | -6.55K | -46.03K | n/a | n/a | n/a | n/a |
Operating Expenses | 14.6M | 12.93M | 5.83M | 5.05M | 4.78M | 4.4M | 4.77M | 6.2M | 4.71M | 4.33M | 4.51M | 4.64M | 4.64M | 5.04M | 4.47M | 2.63M | 2.63M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 5.00 | 158.00 | 157.00 | 7.81K | 11.8K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 14.6M | 12.93M | 5.83M | 5.05M | 4.78M | 4.4M | 4.77M | 6.2M | 4.71M | 4.33M | 4.51M | 4.64M | 4.64M | 5.04M | 4.47M | 2.63M | 2.63M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | 46.17K | 37.12K | -474.34K | -111.83K | n/a | n/a | n/a | -314 | n/a | n/a | n/a |
Shares Outstanding (Basic) | 89.54M | 69.36M | 8.88M | 7.54M | 6.34M | 6.19M | 5.34M | 5.23M | 4.59M | 4.2M | 4.22M | 4.2M | 4.2M | 4.21M | 4.19M | 2.04M | 1.68M |
Shares Outstanding (Diluted) | 89.54M | 69.36M | 8.88M | 7.54M | 6.34M | 6.19M | 5.34M | 5.23M | 4.59M | 4.2M | 4.22M | 4.22M | 4.2M | 4.21M | 4.19M | 2.04M | 1.68M |
EPS (Basic) | -0.15 | -0.51 | -0.65 | -0.66 | -0.73 | -0.68 | -0.86 | -1.11 | -0.87 | -0.99 | -1.06 | -1.1 | -1.1 | -1.2 | -1.07 | -1.29 | -1.57 |
EPS (Diluted) | -0.15 | -0.51 | -0.65 | -0.66 | -0.73 | -0.68 | -0.86 | -1.11 | -0.87 | -0.99 | -1.06 | -1.1 | -1.1 | -1.2 | -1.07 | -1.29 | -1.57 |
EBITDA | -15.75M | -12.92M | -5.82M | -5.04M | -4.78M | -4.4M | -4.76M | -6.04M | -4.71M | -4.33M | -4.51M | -4.64M | -4.64M | -5.04M | -4.47M | -2.63M | -2.63M |
EBIT | -15.76M | -12.93M | -5.83M | -5.05M | -4.78M | -4.4M | -4.77M | -6.2M | -4.71M | -4.33M | -4.51M | -4.64M | -4.64M | -5.04M | -4.47M | -2.63M | -2.63M |
Depreciation & Amortization | 12.65K | 6.57K | 6.57K | 6.57K | 6.57K | 6.57K | 6.57K | 159.2K | 5.04K | 5.04K | 1.68K | 4.64M | 4.64M | 5.04M | 4.47M | 2.63M | 2.63M |